190PD - Research-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies
- Resource Type
- Abstract
- Authors
- Bianchini, G.; Parker, J.; Carey, L.; Perou, C.M.; Sica, L.; Prat, A.; Pieńkowski, T.; Im, Y.-H.; Bianchi, G.V.; Ling-Ming, T.; Liu, M.-C.; Lluch, A.; Semiglazov, V.; de la Haba-Rodriguez, J.; Oh, D.-Y.; Poirier, B.; Pedrini, J.L.; Valagussa, P.; Gianni, L.
- Source
- In Annals of Oncology October 2018 29 Supplement 8
- Subject
- Language
- ISSN
- 0923-7534